The Food and Drug Administration (FDA) has approved Arbli™, an oral suspension formulation of losartan potassium. Arbli, an angiotensin II receptor blocker, is indicated for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback